Vanderbilt Medical Center Clinical Trials 2022

PT2385 for Kidney Cancer

18+

All Sexes

Nashville, TN

This trial is testing a new drug, MK-3795, for patients with advanced kidney cancer. The goal is to find the maximum tolerated dose (MTD) of the drug for future trials.

Phase 1

Waitlist Available

FDA Approved Drug

Learn More

Vanderbilt Medical CenterMedical DirectorPeloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Belzutifan for Kidney Cancer

18+

All Sexes

Nashville, TN

This trial will test if belzutifan can shrink tumors in people with von Hippel-Lindau disease-related kidney cancer.

Phase 2

Waitlist Available

Has No Placebo

Learn More

Vanderbilt Medical CenterMedical DirectorPeloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INCA 0186 Combination Therapy for Cancer

18 - 90

All Sexes

Nashville, TN

This trial is testing a new drug called INCA00186, alone or with other drugs, in patients with advanced head and neck or gastrointestinal cancers that have CD8 T-cells. The treatment uses immunotherapy to help the immune system attack cancer cells.

Phase 1

Waitlist Available

Has No Placebo

Learn More

Vanderbilt Medical CenterIlona Rybicka, MDIncyte Corporation

Is this your site?

Every week patients are viewing your profile. Claim your page to easily update information, respond to patients, and more!

Claim Profile